Excessive generation of reactive oxygen species (ROS) in cancer cells is associated with cancer development, but the underlying mechanisms and therapeutic significance remain elusive. In this study, we reported that levels of ROS and p22(phox) expression are greatly increased in human prostate cancer tissues, and knockdown of p22(phox) by specific small interfering RNA (siRNA) decreased ROS levels in prostate cancer cells. We also showed that stable downregulation of p22(phox) in prostate cancer cells inhibited cell proliferation and colony formation, which was mediated by AKT and extracellular signal-regulated kinase (ERK)1/2 signaling pathways and their downstream molecules hypoxia-inducible factor 1α (HIF-1α) and vascular endothelial growth factor (VEGF). The NADPH oxidase subunit NOX1 was also elevated in prostate cancer cells, and was involved in activation of AKT/ERK/HIF-1/VEGF pathway and regulation of cell proliferation. Knockdown of p22(phox) resulted in inhibition of tumor angiogenesis and tumor growth in nude mice. These findings reveal a new function of p22(phox) in tumor angiogenesis and tumor growth, and suggest that p22(phox) is a potential novel target for prostate cancer treatment.
Keywords: 5-(and-6)-chloromethyl-2′,7′-dichlorodihydrofluorescein diacetate; Angiogenesis; CCK-8; CM-H2DCFDA; Cell Counting Kit-8; DHE; FBS; HIF-1α; MVD; Prostate cancer; ROS; Tumor growth; VEGF; dihydroethidium; fetal bovine serum; hypoxia-inducible factor 1α; microvessel density; p22(phox); reactive oxygen species; vascular endothelial growth factor.
© 2013. Published by Elsevier B.V. All rights reserved.